-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 4, Novartis announced that it had signed a $20.
Novartis and Roche are the world's top pharmaceutical giants, both headquartered in Basel, Switzerland, with office buildings only a few kilometers apart.
Today, Roche is repurchasing these shares for US$20.
Novartis CEO Vas Narasimhan said in a statement: "As a Roche shareholder for more than 20 years, we have concluded that now is the right time to monetize our investment
The return seems considerable: As early as 2001, Novartis spent US$2.
On the other hand, Roche plans to write off the repurchased shares after the debt financing transaction is completed
Therefore, the voting rights of the founding family consortium will increase to 67.
Twenty years ago, the unusual entanglement between the two pharmaceutical giants shocked investors, leading some analysts to predict that they might merge at some point